EMA Authorised: Opzelura (ruxolitinib phosphate) — Incyte Biosciences Distribution B.V.

View source ↗

Summary

EMA has authorised Opzelura (ruxolitinib phosphate) for use in vitiligo and atopic dermatitis, with Incyte Biosciences Distribution B.V. as the marketing author…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis
• Vitiligo

Drugs mentioned

• Opzelura (ruxolitinib)

Snippet

Status: Authorised. Therapeutic area: Vitiligo;Dermatitis, Atopic. MAH: Incyte Biosciences Distribution B.V.. Decision date: 24/07/2026